-
公开(公告)号：US08273342B2
公开(公告)日：2012-09-25
申请号：US12487563
申请日：2009-06-18
CPC分类号： A61K38/21 , A61K31/56 , A61K31/7088 , A61K38/215 , A61K45/06 , A61M16/14 , A61K2300/00
摘要： The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebulizer. Also provided is IFN-λ for the same purpose.
摘要翻译： 本发明提供了IFN-α和bgr的使用，IFN-α和bgr的表达增加，或能够表达IFN-和bgr的多核苷酸; 或用于制备用于治疗选自哮喘和慢性阻塞性肺疾病的呼吸道疾病的鼻病毒引起的恶化的药物的所述药剂，其中所述治疗是通过所述药物的气道递送，例如， 通过使用气溶胶喷雾器。 还提供了用于相同目的的IFN-λ。
-
公开(公告)号：US09089535B2
公开(公告)日：2015-07-28
申请号：US13587752
申请日：2012-08-16
IPC分类号： A61K38/21 , A61K31/56 , A61K31/7088 , A61K45/06 , A61M16/14
CPC分类号： A61K38/21 , A61K31/56 , A61K31/7088 , A61K38/215 , A61K45/06 , A61M16/14 , A61K2300/00
摘要： The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose.
摘要翻译： 本发明提供了IFN-α和bgr的使用，IFN-α和bgr的表达增加，或能够表达IFN-和bgr的多核苷酸; 或用于制备用于治疗选自哮喘和慢性阻塞性肺疾病的呼吸道疾病的鼻病毒引起的恶化的药物的所述药剂，其中所述治疗是通过所述药物的气道递送，例如， 通过使用气溶胶雾化器。 还提供了用于相同目的的IFN-λ。
-
公开(公告)号：US07569216B2
公开(公告)日：2009-08-04
申请号：US11517763
申请日：2006-09-08
IPC分类号： A61K38/21
CPC分类号： A61K38/21 , A61K31/56 , A61K31/7088 , A61K38/215 , A61K45/06 , A61M16/14 , A61K2300/00
摘要： The present invention provides the use of IFN-β, an agent that increases the expression of IFN-β, or a polynucleotide which is capable of expressing IFN-β or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser. Also provided is IFN-λ for the same purpose.
摘要翻译： 本发明提供IFN-β的用途，IFN-β增加IFN-β的表达，或能够表达IFN-β的多核苷酸或用于制备用于治疗鼻病毒诱导的恶化的药物 选自哮喘和慢性阻塞性肺疾病的呼吸系统疾病，其中所述治疗是通过气道递送所述药物，例如， 通过使用气溶胶雾化器。 还提供了用于相同目的的IFN-λ。
-
公开(公告)号：US07312047B2
公开(公告)日：2007-12-25
申请号：US11135339
申请日：2005-05-24
IPC分类号： C12Q1/02
CPC分类号： G01N33/5044
摘要： The present invention relates to the use of an air-liquid interface culture model using asthmatic bronchial epithelial cells, which exhibit impaired epithelial barrier function. It is proposed to use asthmatic epithelial cultures, in the absence of added Th2 or proinflammatory cytokines such as IL-13, as an in vitro model to screen for agents that can act to improve impaired asthmatic epithelial barrier function. Such agents may have therapeutic utility in asthma patients.
摘要翻译： 本发明涉及使用哮喘性支气管上皮细胞的空气 - 液体界面培养模型，其表现出受损的上皮屏障功能。 建议在没有添加Th2或促炎细胞因子如IL-13的情况下使用哮喘上皮培养物作为体外模型，以筛选可用于改善受损的哮喘上皮屏障功能的药剂。 这些药物可能在哮喘患者中具有治疗效用。
-
-
-
搜索结果
4 条记录 (耗时 0.025 秒)
